More than 320 prescription medications disappeared from American pharmacy shelves during 2024, according to a January 2026 profile of the drugmaker HRV Pharma. Cancer patients could not get chemotherapy drugs. Children with ADHD went without the medication that helped them focus in school. Diabetics faced worries about insulin supply.
The shortage did not end with the year. Over 270 medications were still in short supply at the close of 2024, and nearly half of those shortages had lasted two years or longer. The profile puts the number of active cases at 271 now, down only slightly from the record.
One plant, a national scramble
The fragility showed in September 2024, when Hurricane Helene struck North Carolina and a single Baxter manufacturing plant went offline. Within weeks, 58% of U.S. hospitals considered postponing surgeries because they could not get basic IV fluids.
Patients paid for it directly. Many spent over $1,000 out of pocket on questionable alternatives, the profile says, and others skipped their medications altogether.
Idle factories, not missing ones
The profile argues that the problem is not a shortage of plants. India alone has over 300 FDA-approved pharmaceutical plants, it says, yet most run at just 50-70% capacity when resilience takes 85-90% utilization. Generic drugs are the most exposed, because slim margins discourage competition and one manufacturer’s trouble is felt across the country at once.
The usual remedy, building more factories, takes 5-7 years and billions of dollars. HRV Pharma describes a different route: link FDA-approved, GMP-certified facilities that already exist into one digital network, so production can shift to another plant when one reaches capacity or goes offline. The company calls it the first virtual manufacturing network in the pharmaceutical industry.
HRV says it delivered 14 active pharmaceutical ingredients in 18 months and has over 60 products planned for the next three years. It represents over 30 large Indian drugmakers, operates across six countries and reports revenues exceeding $50 million. The company says it is also expanding beyond India to manufacturers in China, the U.S. and Europe. These figures come from the company’s own account and the profile’s author, and they have not been independently checked here.
When approved drugs vanish, the profile notes, compounded versions of varying quality rush in. The FDA issued safety warnings about them.
